

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 6

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

REMARKS

Claims 37-214 remain pending in the case, claims 45, 55-72, 79 and 90-99 having been amended above. Support for these amendments can be found throughout the application.

Applicants thank the Examiner for telephoning the undersigned on October 2, 2002, to suggest these amendments. It is believed that the amendments to claims 45, 55-72, and 90-99 do not alter the scope of these claims.

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all claims be allowed. Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney docket No. 14539-004001 (note this changed docket number).

Respectfully submitted,

Date:

Oct 18, 2002

Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20517994.doc

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 7

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

Version with markings to show changes made

In the claims:

Claims 45, 55-72, 79 and 90-99 have been amended as follows:

45. The antibody or portion thereof of claim 38, wherein the antibody is a human antibody.

55. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

56. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

57. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

58. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

59. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 8

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

60. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

61. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

62. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

63. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

64. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.

65. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 47.

66. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 48.

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 9

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

67. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 49.

68. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 50.

69. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 51.

70. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 52.

71. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 53.

72. A method of treating [a subject suffering from or at risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 54.

79. An isolated cell that produces the antibody [or portion thereof] of claim 45.

90. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 10

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

91. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

92. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

93. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

94. A method of [preventing] inhibiting activation of lymphocytes in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.

95. A method of treating [a subject suffering from or at a risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 85.

96. A method of treating [a subject suffering from or at a risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 86.

97. A method of treating [a subject suffering from or at a risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 87.

Applicant : Takuya Tamatani et al.
Serial No. : 09/383,551
Filed : August 26, 1999
Page : 11

Attorney's Docket No.: 14539-004001 / J1-802PCT-US

98. A method of treating [a subject suffering from or at a risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 88.

99. A method of treating [a subject suffering from or at a risk of] glomerulonephritis in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 89.